In 2023, the number of multidrug-resistant tuberculosis (MDR-TB) cases started on treatment in the US was approximately 119 cases. Predictions from 2024 to 2028 reveal a stable scenario with cases remaining between 119 and 120. Year-over-year, there’s negligible growth with variations close to zero, suggesting efforts to control MDR-TB have maintained but not significantly reduced occurrences.
Future trends to watch for include:
- Emerging treatment protocols that may impact case numbers.
- Global health policy changes affecting disease management.
- Technological advancements in diagnostics and therapies.
- Potential rise due to factors like pandemic impacts on general healthcare services.
